Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 5,400.00
-230.00 (-4.09%)
At close: Jun 12, 2026
Genome & Company Market Cap
Genome & Company has a market cap or net worth of 241.42 billion as of June 12, 2026. Its market cap has increased by 206.37% in one year.
Market Cap
241.42B
Enterprise Value
221.42B
Revenue
24.02B
Ranking
n/a
PE Ratio
n/a
Stock Price
5,400.00
Market Cap Chart
Since December 26, 2018, Genome & Company's market cap has increased from 71.88B to 241.42B, an increase of 235.88%. That is a compound annual growth rate of 17.62%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 12, 2026 | 241.42B | 1.27% |
| Dec 30, 2025 | 238.38B | 179.77% |
| Dec 30, 2024 | 85.21B | -51.64% |
| Dec 28, 2023 | 176.21B | -28.34% |
| Dec 29, 2022 | 245.90B | -47.55% |
| Dec 30, 2021 | 468.83B | -55.28% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| S.Biomedics | 389.51B |
| HansBiomed | 362.24B |
| IntoCell | 335.74B |
| curacle co.,ltd. | 255.65B |
| Kanaph Therapeutics | 255.57B |
| Kangstem Biotech | 252.07B |
| NIBEC | 218.49B |
| Y-Biologics | 212.34B |